



Published in final edited form as:

Curr Opin Lipidol. 2019 October ; 30(5): 357–363. doi:10.1097/MOL.0000000000000632.

Regulation of Calcific Vascular and Valvular Disease by Nuclear Receptors

Tamer Sallam^{1,2,5}, Yin Tintut^{1,2,3}, Linda L. Demer^{1,2,4}

¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1679

²Department of Physiology, University of California, Los Angeles, Los Angeles, CA 90095-1679

³Department of Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, CA 90095-1679

⁴Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095-1679

⁵Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095-1679

Abstract

Purpose of review: This review addresses recent developments in studies of lipid regulation of calcific disease of arteries and cardiac valves, including the role of nuclear receptors. The role of lipid-soluble signals and their receptors is timely given the recent evidence and concerns that lipid-lowering treatment may increase the rate of progression of coronary artery calcification, which has been long associated with increased cardiovascular risk. Understanding the mechanisms will be important for interpreting such clinical information.

Recent findings: New findings support regulation of calcific vascular and valvular disease by nuclear receptors, including the vitamin D receptor, glucocorticoid receptor, nutrient-sensing nuclear receptors (liver X receptor, farnesoid X receptor, and peroxisome proliferator-activated receptors), and sex hormone (estrogen and androgen) receptors. There were two major unexpected findings: First, vitamin D supplementation, which was previously believed to prevent or reduce vascular calcification, showed no cardiovascular benefit in large randomized, controlled trials. Second, both epidemiological studies and coronary intravascular ultrasound studies suggest that treatment with HMG-CoA reductase inhibitors increases progression of coronary artery calcification, raising a question of whether there are mechanically stable and unstable forms of coronary calcification.

Summary: For clinical practice and research, these new findings offer new fundamental mechanisms for vascular calcification and provide new cautionary insights for therapeutic avenues.

Corresponding author: Linda L. Demer, MD, PhD, Division of Cardiology, Department of Medicine, Center for Health Sciences A2-237, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679, Phone: (310) 206-2677, LDemer@mednet.ucla.edu.

Conflicts of interest
None

Keywords

vascular; calcification; *bone*; *lipoproteins*; *atherosclerosis*

Introduction

This review is focused on lipids and mineralization, specifically the contributions of nuclear receptors to calcific vascular and valvular diseases (CVVD) as well as interactions between therapies for osteoporosis and cardiovascular disease. A number of recent reviews have considered other aspects of these disorders, including the roles of oxidized lipoproteins [1], lipoprotein(a) [2], and both [3]; the unique manifestations in patients with chronic kidney disease [4], affecting primarily the medial layer of vessels [5]; the role of matrix vesicles and extracellular vesicles [6, 7]; potential inhibition by vitamin K and its relationship to clinical warfarin therapy [8]; potential artifacts in imaging [9]; and biomechanical factors [10].

Nuclear receptors

A number of landmark studies in the 1980s provided unequivocal evidence that structurally related transcription factors can directly interact with endogenous signaling molecules to specify physiologic effects [11], launching the field of nuclear receptor biology. Today, much is known about the functional domains, interacting partners, and preferential DNA binding patterns of the 48 members of this superfamily [12]. This research has provided fundamental insights into contributions of gene regulatory mechanisms in health and disease.

In general, nuclear receptors are activated inside of cells in response to hormones or lipid soluble signals such as estrogen, retinoic acid or vitamin D [13]. They can exist as monomers, homodimers or heterodimers and bind specific DNA sequences to induce or repress the expression of target genes upon ligand stimulation [13]. Not surprisingly, the ability of nuclear receptors to serve as important conduits between environmental clues and gene expression is absolutely critical to the maintenance of vascular homeostasis and bone turnover. Dysregulation in nuclear receptor pathways can lead to a number of pathologic states including cardiac calcification, atherogenesis, and abnormal skeletal mineralization. We review below the contributions of specific nuclear receptors in calcific vascular disease.

Vitamin D receptor

In recent years, vitamin D has received widespread attention due to a campaign targeting physicians to measure levels and treat presumed deficiency [14]. Based on observational studies, which had unavoidable biases, it was believed that vitamin D supplementation would prevent cardiovascular disease as well as numerous other diseases including cancer. However, recent results from the VITAL [15] and J-DAVID [16] randomized, controlled trials showed that vitamin D supplementation fails to reduce risk of cardiovascular or other diseases. Thus, the campaign led to a marked increase in the number of tests for blood levels and an increased rate of clinical hypervitaminosis D from excess supplementation without demonstrable benefit [15]. The past few years have seen a global increase in 25(OH)D levels

in the general population attributed to excess vitamin D supplementation [17], and this may increase the risk of calcific vascular and valvular disease worldwide [18].

As background, the dihydroxy- form of vitamin D [1,25(OH)₂D] is the active form, which is a ligand for the vitamin D receptor (VDR), which regulates calcium and phosphate homeostasis. The level of the monohydroxy- form [25(OH)D] is an indicator of the adequacy of stores. Activation of 25(OH)D to the dihydroxy form occurs by the action of 1- α hydroxylase, located primarily in the kidney, but also in the vasculature and in activated immune cells [19]. Thus, chronic kidney disease requires supplementation with the active form. VDR forms a permissive heterodimer with retinoid X receptor (RXR) and, upon stimulation of its ligand-binding domain by 1,25(OH)₂D, it is capable of regulating a specific subset of genes that mediate calcium/phosphate transport and bone turnover, such as osteocalcin, osteopontin, transient receptor potential (TRPV6, which functions in renal calcium resorption), parathyroid hormone (PTH), and its related peptide (PTHrP), Cyp24a1 (24-hydroxylase, which limits formation of active vitamin D) and Cyp27b1 (1 α -hydroxylase, which converts the monohydroxy- to the dihydrox- form) [19]. VDR also collaborates with other transcriptional regulators, such as RUNX2, which is considered a central factor in osteoblastic differentiation of vascular cells [20].

Excess vitamin D intake, leading to hypervitaminosis D, has been a known cause of vascular calcification for almost a century [18]. Administration of vitamin D to mice, rats, rabbits, and pigs is widely used as an experimental model for vascular, renal, and pulmonary calcification [21–24]. A recent report raises the possibility of that fibroblast growth factor 21 may mitigate vitamin D-induced vascular calcification [25], but therapies, other than discontinuing unnecessary supplementation, are not established. Thus, unmonitored, prolonged, and empirical vitamin D supplementation carries risk of widespread calcific cardiovascular disease [17].

At the same time, extremely low levels of vitamin D, hypovitaminosis D, have also been associated, to a lesser degree, with vascular calcification. Epidemiologically, the links between low vitamin D levels and poor health in human observational studies are confounded by the fact that infirm individuals typically have limited sun exposure. That is, illness causing low vitamin D may account for the associations. Recent studies in mice, though, show that low dietary vitamin D is also associated with vascular calcification in wild type, LDLR null mice [26] and apolipoprotein E null mice [27]. But the degree of vascular calcification caused by low dietary vitamin D was much less than that caused by excess vitamin D. In mice deficient in VDR, aortic calcification was reported [27], but it was only on the valve leaflets where pigmentation may be mistakenly identified as calcification by von Kossa histochemical stain. Humans with loss-of-function mutations in VDR, known as hereditary vitamin D resistant rickets [28], are not known to have vascular calcification, though possibly because of the young age of subjects. Interpretation of the findings in VDR mutants is complex, given that there are ligand-independent effects of VDR, such as alopecia and gut-adipose crosstalk [29].

These results are consistent with the notion that the relationship between vitamin D and vascular calcification is complex, and multiple redundant regulatory circuits work

cooperatively to regulate its levels, including a negative feedback loop through 24-hydroxylase. Adding another layer of complexity is that serum vitamin D level, often used as surrogate marker of vitamin D activity in clinical practice and investigative studies, does not generally reflect VDR transcriptional output and signaling [30, 31].

It is well established that inflammation augments vascular calcification. Although VDR is abundantly expressed in immune-cells and has potent anti-inflammatory properties [32–35], these effects are likely minor compared with the pro-mineralization effects of hypervitaminosis D. Intriguingly, statins, which possess potent anti-inflammatory properties and overall favorable effects on cardiovascular outcomes, have been shown to accelerate vascular calcification [36]. Thus, it is tempting to speculate, based on these observations, that sustained immune suppression or direct effects of statins on 25(OH)D levels and VDR activity [37, 38] may contribute to vascular mineralization. With recent guidelines placing a stronger emphasis on use of calcium scans in cardiovascular risk stratification [39], a better understanding of the connections between statins, vitamin D, and vascular calcification has become essential.

Glucocorticoid Receptor

One of the most widely studied nuclear receptors, the glucocorticoid receptor (GR), has an established role in potently inhibiting inflammation. GR is ubiquitously expressed, and insights into the contributions of GR to vascular mineralization stem from well-known side effects of glucocorticoids (GC) on bone, including increased turnover. Activation of GR is known to modulate osteoblast and osteoclast differentiation and function, resulting in reduced bone mass. It also leads to induction of receptor activator of nuclear factor-kappa B ligand (RANKL), which promotes osteoclast differentiation, and it also suppresses osteoblast-derived cytokines such as IL-11 [40]. In vascular pericytes, which may be the origin of at least some resident vascular pre-osteoblastic cells [41], GC treatment leads to enhanced osteogenic differentiation, effects that were abolished with GR antagonist treatment [42]. In addition, GR signaling in macrophages may contribute to vascular calcification. Deletion of the GR in macrophages showed no effect on atherosclerosis burden, but it attenuated vascular calcification and expression of osteogenic factors RANKL, BMP2, and Msx2 [43]. More recent evidence has linked GR activation with cancer metastasis, a feature that may lead to eventual arteriolar calcification [44]. In addition to activating GR, the effects of steroids on vascular calcification are thought to be, at least in part, mediated by the closely related mineralocorticoid receptor [45], whose activation leads to osteoblastic differentiation and mineralization of vascular smooth muscle cells [46]. The structurally related growth hormone-releasing hormone (GHRH) has been recently shown to inhibit vascular calcification through regulation of inflammation-mediated osteogenesis [47]. Thus, multiple lines of evidence support the notion that GR plays an important role in VC, but whether the observed effects are due to direct transcriptional activities of GR remains unclear.

Nutrient-sensing nuclear receptors (LXR, FXR, and PPARs)

Liver X receptors (LXRs) are sterol-sensing nuclear receptors with critical roles in regulating lipid metabolism. Like other nuclear receptors, LXRs are activated upon

stimulation of their ligand-binding domain. In response to accumulation of oxysterols, they exchange transcriptional corepressors with coactivators to potently inhibit inflammation and to induce the expression of genes involved in cholesterol efflux, triglyceride synthesis, lipid uptake, phospholipid composition, and cholesterol feedback [48]. LXR activation *in vitro* has been shown to augment vascular cell calcification induced by PKA signaling [49], while loss of LXR function attenuates this effect [50]. The mechanism may be related to LXR-mediated increases in lipogenesis [50]. Similar in some respect to LXRs, farnesoid X receptors (FXRs) are bile-acid sensors that play important roles in cholesterol and bile acid regulation. Activation of FXR in calcifying vascular cells reduces triglyceride accumulation and inhibits mineralization [51]. In addition, activation of FXR *in vivo* reduces vascular calcification without impacting atherosclerosis development, possibly via JNK phosphorylation [51]. In contrast, in bone marrow stromal cells, FXR activation increases calcification [52], suggesting context-dependence. Finally, activation of the peroxisome proliferator-activated receptors (PPARs), the targets of thiazolidinedione drugs, inhibits vascular calcification through favorable metabolic effects that lead to upregulation of Klotho or modulation of WNT signaling [53–55]. In general, precise mechanisms as to how nutrient-sensing nuclear receptors may regulate vascular calcification remain undefined. Direct transcriptional control of canonical regulators of bone mineralization has not been shown. A common thread, however, to the activity of the above nuclear receptors is regulation of inflammatory activation as well as modulation of intracellular stearate and lipid content with downstream ossification [50]. Development of selective modulators of LXR and FXR has been of immense interest owing to the favorable effects of these receptors on atherosclerosis (LXR), cancer (LXR) and fatty liver diseases (FXR). A number of compounds are currently in various stages of clinical development, which should provide more insights into the contributions of these receptors to human vascular calcification.

Sex hormone receptors (ER and AR)

The role of estrogen in cardiovascular health and disease has been a controversial topic, both with respect to hormone replacement therapy in patients and with respect to effects on vascular calcification. Estrogen activates two subtypes of estrogen receptor (ER), ER-alpha and ER-beta. While some *in vitro* studies had shown 17beta-estradiol (E2) inhibited vascular cell calcification [56, 57], one showed E2 stimulated vascular cell calcification [58]. A more definitive study showed not only stimulation of osteogenic calcification in vascular cells by E2, but also *in vivo* stimulation of osteogenic calcification in aged (atherosclerotic) ApoE null mice of both sexes [59]. In a seeming paradox, they also found that direct antagonism of either alpha or beta subtypes of ER also promoted vascular calcification, but it was consistent with their finding that E2 suppressed expression of ER-beta [59], suggesting an inhibitory feedback mechanism, non-genomic effects of E2, or cross-talk with other co-activators or nuclear receptors in the presence of excess E2.

One mechanism by which estrogen may influence vascular calcification is through upregulation of BMP-2 [60, 61]. The involvement of other sex hormones, such as the androgen receptor (AR), in vascular calcification remains unclear with studies showing opposing effects of AR activation on vascular calcification [62, 63]. With respect to human calcific disease, recent evidence from the large, NIH-funded Multi-ethnic Studies of

Atherosclerosis (MESA) indicates that baseline sex hormone levels are not associated with coronary calcium score, but that higher free testosterone levels associate with greater CAC progression at up to 10-years in post-menopausal women [64]. Overall, potential therapeutic directions based on associations need to take into consideration potential confounding due to effects of patient compliance and its correlation with health lifestyle [65].

Relations to skeletal calcification

Calcific atherosclerosis and osteoporosis often co-exist in patients [66], as do coronary artery disease and osteoporosis [67–70]. One possible mechanism for this reciprocal relationship between artery and bone mineral deposition is that proatherogenic lipid oxidation products, increased by high-fat diets, promote osteoblastic differentiation of vascular smooth muscle cells while they inhibit differentiation and mineralization in skeletal osteoblasts [71]. Hyperlipidemia, whether due to genetic modification or a high-fat diet, reduces bone mineral density in mouse models [72–75].

Effects of cardiovascular therapies on osteoporosis

The effects of lowering serum lipids on osteoporosis remain unclear. When lipid-oxidation products were neutralized in mice, high-fat-diet-induced bone loss was reversed [76]. However, effects of lipid-lowering, and statin treatment in particular, on bone have been controversial. Recent observational studies report improvement in bone health [77–79], however, randomized controlled trials, which are far more reliable, fail to confirm those findings, likely because patients adhering to one healthy regimen adhere to other healthy regimens as well [65].

Effects of osteoporosis therapies on cardiovascular disease

Two types of osteoporosis treatments, teriparatide, a bone anabolic agent, and bisphosphonate, an anti-resorptive agent, impact the cardiovascular system. Effects of teriparatide are of particular concern, because of its pro-mineralization functions. One earlier study showed that teriparatide actually inhibits initiation of cardiovascular calcification [80]. In a recent study in hyperlipidemic mice with basal cardiovascular calcification, teriparatide did not appear to affect the progression of aortic calcification, at least in terms of content [81]. However, it did appear to reduce surface area of vascular calcium deposits, based on histologic analysis, which could affect plaque stability [81]. For about three decades, bisphosphonates have been proposed as treatments for atherosclerotic calcification, given their similarity to the potent endogenous inhibitor, pyrophosphate. The concern has been that the doses required are toxic, and the clinical use of bisphosphonates is limited in duration due to adverse effects. However, this may be open to reconsideration based on a recent report of a novel bisphosphonate that shows 10-fold greater potency than etidronate, in inhibiting aortic calcification induced by vitamin D in rats [82].

Lastly, cardiovascular therapy may actually influence the efficacy of osteoporosis therapy, based on results of a small, retrospective study of 52 patients treated with teriparatide for severe osteoporosis. The degree of improvement in bone density depended on baseline lipid

profiles: bone density improved more in patients with favorable baseline lipid profiles (low LDL-cholesterol and high HDL-cholesterol) and less in patients with unfavorable baseline lipid profiles [83].

Conclusion

Growing evidence links lipids and lipid oxidation products to regulation of calcium mineralization, in arteries and cardiac valves as well as in skeletal bone. Nuclear receptors and their ligands contribute in a variety of ways. Both excess and deficiency of vitamin D promote vascular calcification. Activation of liver X receptor promotes vascular calcification whereas activation of farnesoid X receptor or PPAR inhibit it. 17beta-estradiol appears to promote vascular calcification. Lipid-lowering therapies for cardiovascular disease may affect osteoporosis, whereas bone anabolic therapies for osteoporosis may affect cardiovascular disease. Moreover, lipid-lowering therapy may impact efficacy of bone anabolic treatment. Observational studies of effects of lipid-lowering on bone are subject to confounding because adherence to treatments, even placebos, correlates with healthier outcomes. Randomized controlled trials are needed to test the potential value of lipid-lowering for osteoporosis.

Acknowledgments

Financial support and sponsorship

This work was supported in part by funding from the National Institutes of Health [HL139549, DK118086, AG061586, and HL137647].

References

- [1]. Tintut Y, Hsu JJ, Demer LL. Lipoproteins in Cardiovascular Calcification: Potential Targets and Challenges. *Front Cardiovasc Med* 2018; 5:172. [PubMed: 30533416]
- [2]. Saeed A, Virani SS. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. *Front Biosci (Landmark Ed)* 2018; 23:1099–1112. [PubMed: 28930591]
- [3]. Yeang C, Wilkinson MJ, Tsimikas S. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. *Curr Opin Cardiol* 2016; 31:440–450. [PubMed: 27205885]
- [4]. Yamada S, Giachelli CM. Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho. *Bone* 2017; 100:87–93. [PubMed: 27847254]
- [5]. Ho CY, Shanahan CM. Medial Arterial Calcification: An Overlooked Player in Peripheral Arterial Disease. *Arterioscler Thromb Vasc Biol* 2016; 36:1475–1482. [PubMed: 27312224]
- [6]. Blaser MC, Aikawa E. Roles and Regulation of Extracellular Vesicles in Cardiovascular Mineral Metabolism. *Front Cardiovasc Med* 2018; 5:187. [PubMed: 30622949]
- [7]. Bottini M, Mebarek S, Anderson KL et al. Matrix vesicles from chondrocytes and osteoblasts: Their biogenesis, properties, functions and biomimetic models. *Biochim Biophys Acta Gen Subj* 2018; 1862:532–546. [PubMed: 29108957]
- [8]. Siltari A, Vapaatalo H. Vascular Calcification, Vitamin K and Warfarin Therapy - Possible or Plausible Connection? *Basic Clin Pharmacol Toxicol* 2018; 122:19–24. [PubMed: 28639365]
- [9]. Demer LL, Tintut Y, Nguyen KL et al. Rigor and Reproducibility in Analysis of Vascular Calcification. *Circ Res* 2017; 120:1240–1242. [PubMed: 28408452]
- [10]. Thondapu V, Bourantas CV, Foin N et al. Biomechanical stress in coronary atherosclerosis: emerging insights from computational modelling. *Eur Heart J* 2017; 38:81–92. [PubMed: 28158723]

- [11]. Evans RM, Mangelsdorf DJ. Nuclear Receptors, RXR, and the Big Bang. *Cell* 2014; 157:255–266. [PubMed: 24679540]
- [12]. Lazar MA. Maturing of the nuclear receptor family. *J Clin Invest* 2017; 127:1123–1125. [PubMed: 28368290]
- [13]. Sever R, Glass CK. Signaling by nuclear receptors. *Cold Spring Harb Perspect Biol* 2013; 5:a016709. [PubMed: 23457262]
- [14]. Rodd C, Sokoro A, Lix LM et al. Increased rates of 25-hydroxy vitamin D testing: Dissecting a modern epidemic. *Clin Biochem* 2018; 59:56–61. [PubMed: 30026017]
- [15] ••. Manson JE, Cook NR, Lee IM et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. *N Engl J Med* 2019; 380:33–44. [PubMed: 30415629] This large randomized clinical trial showed that treatment with vitamin D supplements and fish oil failed to confer benefit on cardiovascular disease, suggesting that prior observational studies were confounded by healthy-adherer effects.
- [16]. Investigators JD, Shoji T, Inaba M et al. Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial. *JAMA* 2018; 320:2325–2334. [PubMed: 30535217]
- [17]. Sharma LK, Dutta D, Sharma N, Gadpayle AK. The increasing problem of subclinical and overt hypervitaminosis D in India: An institutional experience and review. *Nutrition* 2017; 34:76–81. [PubMed: 28063517]
- [18]. Demer LL, Hsu JJ, Tintut Y. Steroid Hormone Vitamin D: Implications for Cardiovascular Disease. *Circ Res* 2018; 122:1576–1585. [PubMed: 29798901]
- [19]. Pike JW, Meyer MB. The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). *Endocrinol Metab Clin North Am* 2010; 39:255–269, table of contents. [PubMed: 20511050]
- [20]. Han MS, Che X, Cho GH et al. Functional cooperation between vitamin D receptor and Runx2 in vitamin D-induced vascular calcification. *PLoS One* 2013; 8:e83584. [PubMed: 24349534]
- [21]. Carmo LS, Burdmann EA, Fessel MR et al. Expansive Vascular Remodeling and Increased Vascular Calcification Response to Cholecalciferol in a Murine Model of Obesity and Insulin Resistance. *Arterioscler Thromb Vasc Biol* 2019; 39:200–211. [PubMed: 30580565]
- [22]. Demer LL. Effect of calcification on in vivo mechanical response of rabbit arteries to balloon dilation. *Circulation* 1991; 83:2083–2093. [PubMed: 2040058]
- [23]. Kingma JG Jr., Roy PE. Ultrastructural study of hypervitaminosis D induced arterial calcification in Wistar rats. *Artery* 1988; 16:51–61. [PubMed: 3207390]
- [24]. Quarterman J, Dalgarno AC, Adam A et al. The Distribution of Vitamin D between the Blood and the Liver in the Pig, and Observations on the Pathology of Vitamin D Toxicity. *Br J Nutr* 1964; 18:65–77. [PubMed: 14112971]
- [25]. Shi Y, Lu W, Hou Y et al. Fibroblast growth factor 21 ameliorates vascular calcification by inhibiting osteogenic transition in vitamin D3 plus nicotine-treated rats. *Biochem Biophys Res Commun* 2018; 495:2448–2455. [PubMed: 29273504]
- [26]. Schmidt N, Brandsch C, Schutkowski A et al. Dietary vitamin D inadequacy accelerates calcification and osteoblast-like cell formation in the vascular system of LDL receptor knockout and wild-type mice. *J Nutr* 2014; 144:638–646. [PubMed: 24647396]
- [27]. Ellam T, Hameed A, ul Haque R et al. Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice. *PLoS One* 2014; 9:e88767. [PubMed: 24586387]
- [28]. Malloy PJ, Feldman D. The role of vitamin D receptor mutations in the development of alopecia. *Mol Cell Endocrinol* 2011; 347:90–96. [PubMed: 21693169]
- [29]. Jahn D, Dorbath D, Schilling AK et al. Intestinal vitamin D receptor modulates lipid metabolism, adipose tissue inflammation and liver steatosis in obese mice. *Biochim Biophys Acta Mol Basis Dis* 2019; 1865:1567–1578. [PubMed: 30905785]
- [30]. Christakos S, Dhawan P, Verstuyf A et al. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. *Physiol Rev* 2016; 96:365–408. [PubMed: 26681795]
- [31]. Wang J, Zhou JJ, Robertson GR, Lee VW. Vitamin D in Vascular Calcification: A Double-Edged Sword? *Nutrients* 2018; 10.

- [32]. Ishii M, Yamaguchi Y, Isumi K et al. Transgenic Mice Overexpressing Vitamin D Receptor (VDR) Show Anti-Inflammatory Effects in Lung Tissues. *Inflammation* 2017; 40:2012–2019. [PubMed: 28803336]
- [33]. Ge X, Wang L, Li M et al. Vitamin D/VDR signaling inhibits LPS-induced IFN γ and IL-1 β in Oral epithelia by regulating hypoxia-inducible factor-1 α signaling pathway. *Cell Commun Signal* 2019; 17:18. [PubMed: 30813930]
- [34]. Rafique A, Rejnmark L, Heickendorff L, Moller HJ. 25(OH)D3 and 1.25(OH)2D3 inhibits TNF- α expression in human monocyte derived macrophages. *PLoS One* 2019; 14:e0215383. [PubMed: 30978243]
- [35]. Sassi F, Tamone C, D'Amelio P. Vitamin D: Nutrient, Hormone, and Immunomodulator. *Nutrients* 2018; 10.
- [36]. Puri R, Nicholls SJ, Shao M et al. Impact of statins on serial coronary calcification during atheroma progression and regression. *J Am Coll Cardiol* 2015; 65:1273–1282. [PubMed: 25835438]
- [37]. Grimes DS. Are statins analogues of vitamin D? *Lancet* 2006; 368:83–86. [PubMed: 16815382]
- [38]. Yavuz B, Ertugrul DT. Statins and vitamin D: A hot topic that will be discussed for a long time. *Dermatoendocrinol* 2012; 4:8–9. [PubMed: 22870345]
- [39]. Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. *Circulation* 2019; CIR0000000000000678.
- [40]. Rauch A, Seitz S, Baschant U et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. *Cell Metab* 2010; 11:517–531. [PubMed: 20519123]
- [41]. Bostrom K, Watson KE, Horn S et al. Bone morphogenetic protein expression in human atherosclerotic lesions. *J Clin Invest* 1993; 91:1800–1809. [PubMed: 8473518]
- [42]. Kirton JP, Wilkinson FL, Canfield AE, Alexander MY. Dexamethasone downregulates calcification-inhibitor molecules and accelerates osteogenic differentiation of vascular pericytes: implications for vascular calcification. *Circ Res* 2006; 98:1264–1272. [PubMed: 16627786]
- [43]. Preusch MR, Rattazzi M, Albrecht C et al. Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse-model of atherosclerosis. *Arterioscler Thromb Vasc Biol* 2008; 28:2158–2164. [PubMed: 18787189]
- [44]. Obradovic MMS, Hamelin B, Manevski N et al. Glucocorticoids promote breast cancer metastasis. *Nature* 2019; 567:540–544. [PubMed: 30867597]
- [45]. Zhu D, Rashdan NA, Chapman KE et al. A novel role for the mineralocorticoid receptor in glucocorticoid driven vascular calcification. *Vascul Pharmacol* 2016; 86:87–93. [PubMed: 27153999]
- [46]. Jaffe IZ, Tintut Y, Newfell BG et al. Mineralocorticoid receptor activation promotes vascular cell calcification. *Arterioscler Thromb Vasc Biol* 2007; 27:799–805. [PubMed: 17234727]
- [47]. Shen J, Zhang N, Lin YN et al. Regulation of Vascular Calcification by Growth Hormone-Releasing Hormone and Its Agonists. *Circ Res* 2018; 122:1395–1408. [PubMed: 29618597]
- [48]. Wang B, Tontonoz P. Liver X receptors in lipid signalling and membrane homeostasis. *Nat Rev Endocrinol* 2018.
- [49]. Hsu JJ, Lu J, Huang MS et al. T0901317, an LXR agonist, augments PKA-induced vascular cell calcification. *FEBS Lett* 2009; 583:1344–1348. [PubMed: 19327357]
- [50]. Ting TC, Miyazaki-Anzai S, Masuda M et al. Increased lipogenesis and stearate accelerate vascular calcification in calcifying vascular cells. *J Biol Chem* 2011; 286:23938–23949. [PubMed: 21596756]
- [51]. Miyazaki-Anzai S, Levi M, Kratzer A et al. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE $^{-/-}$ mice with chronic kidney disease. *Circ Res* 2010; 106:1807–1817. [PubMed: 20431060]
- [52]. Id Boufker H, Lagneaux L, Fayyad-Kazan H et al. Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts. *Bone* 2011; 49:1219–1231. [PubMed: 21893226]

- [53]. Cheng L, Zhang L, Yang J, Hao L. Activation of peroxisome proliferator-activated receptor gamma inhibits vascular calcification by upregulating Klotho. *Exp Ther Med* 2017; 13:467–474. [PubMed: 28352317]
- [54]. Feng H, Wang JY, Yu B et al. Peroxisome Proliferator-Activated Receptor-gamma Coactivator-1alpha Inhibits Vascular Calcification Through Sirtuin 3-Mediated Reduction of Mitochondrial Oxidative Stress. *Antioxid Redox Signal* 2019.
- [55]. Woldt E, Terrand J, Mlih M et al. The nuclear hormone receptor PPARgamma counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells. *Nat Commun* 2012; 3:1077. [PubMed: 23011131]
- [56]. Lu Q, Xiang DX, Yuan HY et al. Puerarin attenuates calcification of vascular smooth muscle cells. *Am J Chin Med* 2014; 42:337–347. [PubMed: 24707866]
- [57]. Rzewuska-Lech E, Jayachandran M, Fitzpatrick LA, Miller VM. Differential effects of 17beta-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins. *Am J Physiol Endocrinol Metab* 2005; 289:E105–112. [PubMed: 15713688]
- [58]. Balica M, Bostrom K, Shin V et al. Calcifying subpopulation of bovine aortic smooth muscle cells is responsive to 17 beta-estradiol. *Circulation* 1997; 95:1954–1960. [PubMed: 9107185]
- [59] •• McRobb LS, McGrath KCY, Tsatralis T et al. Estrogen Receptor Control of Atherosclerotic Calcification and Smooth Muscle Cell Osteogenic Differentiation. *Arterioscler Thromb Vasc Biol* 2017; 37:1127–1137. [PubMed: 28473445] This study provides both in vivo and in vitro evidence that estradiol promotes vascular calcification.
- [60]. Osako MK, Nakagami H, Koibuchi N et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. *Circ Res* 2010; 107:466–475. [PubMed: 20595654]
- [61]. Kim JH, Choi YK, Do JY et al. Estrogen-Related Receptor gamma Plays a Key Role in Vascular Calcification Through the Upregulation of BMP2 Expression. *Arterioscler Thromb Vasc Biol* 2015; 35:2384–2390. [PubMed: 26404484]
- [62]. Son BK, Akishita M, Iijima K et al. Androgen receptor-dependent transactivation of growth arrest-specific gene 6 mediates inhibitory effects of testosterone on vascular calcification. *J Biol Chem* 2010; 285:7537–7544. [PubMed: 20048160]
- [63]. Zhu D, Hadoke PW, Wu J et al. Ablation of the androgen receptor from vascular smooth muscle cells demonstrates a role for testosterone in vascular calcification. *Sci Rep* 2016; 6:24807. [PubMed: 27095121]
- [64]. Subramanya V, Zhao D, Ouyang P et al. Association of endogenous sex hormone levels with coronary artery calcium progression among post-menopausal women in the Multi-Ethnic Study of Atherosclerosis (MESA). *J Cardiovasc Comput Tomogr* 2019; 13:41–47.
- [65]. Donzelli A, Battaggia A, Schivalocchi A. Statin use does not protect from fractures: the healthy adherer effect is a plausible explanation in observational studies. *Osteoporos Int* 2017; 28:2739–2740. [PubMed: 28555283]
- [66]. Yesil Y, Ulger Z, Halil M et al. Coexistence of osteoporosis (OP) and coronary artery disease (CAD) in the elderly: it is not just a by chance event. *Arch Gerontol Geriatr* 2012; 54:473–476. [PubMed: 21723624]
- [67]. Barengolts EI, Berman M, Kukreja SC et al. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. *Calcif Tissue Int* 1998; 62:209–213. [PubMed: 9501953]
- [68]. Schulz E, Arfai K, Liu X et al. Aortic calcification and the risk of osteoporosis and fractures. *J Clin Endocrinol Metab* 2004; 89:4246–4253. [PubMed: 15356016]
- [69]. Tamaki J, Iki M, Hirano Y et al. Low bone mass is associated with carotid atherosclerosis in postmenopausal women: the Japanese Population-based Osteoporosis (JPOS) Cohort Study. *Osteoporos Int* 2009; 20:53–60. [PubMed: 18496639]
- [70]. Yamaguchi T, Sugimoto T, Yano S et al. Plasma lipids and osteoporosis in postmenopausal women. *Endocr J* 2002; 49:211–217. [PubMed: 12081241]
- [71]. Parhami F, Morrow AD, Balucan J et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. *Arterioscler Thromb Vasc Biol* 1997; 17:680–687. [PubMed: 9108780]

- [72]. Drake TA, Schadt E, Hannani K et al. Genetic loci determining bone density in mice with diet-induced atherosclerosis. *Physiol Genomics* 2001; 5:205–215. [PubMed: 11328966]
- [73]. Lac G, Cavalie H, Ebal E, Michaux O. Effects of a high fat diet on bone of growing rats. Correlations between visceral fat, adiponectin and bone mass density. *Lipids Health Dis* 2008; 7:16. [PubMed: 18442361]
- [74]. Parhami F, Tintut Y, Beamer WG et al. Atherogenic high-fat diet reduces bone mineralization in mice. *J Bone Miner Res* 2001; 16:182–188. [PubMed: 11149483]
- [75]. Xiao Y, Cui J, Li YX et al. Dyslipidemic high-fat diet affects adversely bone metabolism in mice associated with impaired antioxidant capacity. *Nutrition* 2010; 27(2):214–220. [PubMed: 20392601]
- [76] ••. Ambrogini E, Que X, Wang S et al. Oxidation-specific epitopes restrain bone formation. *Nat Commun* 2018; 9:2193. [PubMed: 29875355] This important report shows that mice expressing an IgM fragment of E06, which neutralizes epitopes of products of phospholipid oxidation, are resistant to hyperlipidemia-induced bone loss, and even have greater bone mass than control mice on chow diets. This demonstration has major implications for osteoporosis and its treatment.
- [77]. Chiadika SM, Shobayo FO, Naqvi SH et al. Lower femoral neck bone mineral density (BMD) in elderly women not on statins. *Women Health* 2019:1–9.
- [78]. Lin TK, Chou P, Lin CH et al. Long-term effect of statins on the risk of new-onset osteoporosis: A nationwide population-based cohort study. *PLoS One* 2018; 13:e0196713. [PubMed: 29723231]
- [79]. Lin TK, Liou YS, Lin CH et al. High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. *Clin Epidemiol* 2018; 10:159–165. [PubMed: 29403315]
- [80]. Shao JS, Cheng SL, Charlton-Kachigian N et al. Teriparatide (human parathyroid hormone (1–34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. *J Biol Chem* 2003; 278:50195–50202. [PubMed: 14504275]
- [81] ••. Hsu JJ, Lu J, Umar S et al. Effects of teriparatide on morphology of aortic calcification in aged hyperlipidemic mice. *Am J Physiol Heart Circ Physiol* 2018; 314:H1203–H1213. [PubMed: 29451816] This study uses fused microCT and 18F-PET together with histological analysis to assess progression of aortic calcification in hyperlipidemic mice in response to teriparatide; results show no effect on progression of calcium content, but a decrease in relative mineral surface area.
- [82] •. Ishida K, Ashizawa N, Matsumoto K et al. Novel bisphosphonate compound FYB-931 preferentially inhibits aortic calcification in vitamin D3-treated rats. *J Bone Miner Metab* 2019. This new bisphosphonate shows 10-fold greater potency than the one currently used for heterotopic calcification at joint replacement sites.
- [83]. Jeon YK, Kim KM, Kim KJ et al. The anabolic effect of teriparatide is undermined by low levels of high-density lipoprotein cholesterol. *Calcif Tissue Int* 2014; 94:159–168. [PubMed: 23907724]

Key points

- Nuclear receptors and their ligands have important and varying effects on vascular calcification.
- Vitamin D in excess promotes vascular calcification; deficiency has similar, though lesser, effects.
- While observational studies suggest that statins benefit bone health, the finding has not been detected in randomized controlled trials.
- Poor lipid profiles may reduce efficacy of bone anabolic therapy for osteoporosis.